Immunoprecise Antibodies Ltd (IPA) - Total Liabilities
Based on the latest financial reports, Immunoprecise Antibodies Ltd (IPA) has total liabilities worth $20.82 Million USD as of April 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Immunoprecise Antibodies Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Immunoprecise Antibodies Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Immunoprecise Antibodies Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Immunoprecise Antibodies Ltd assets under control.
Immunoprecise Antibodies Ltd Competitors by Total Liabilities
The table below lists competitors of Immunoprecise Antibodies Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apex Biotechnology Corp
TW:1733
|
Taiwan | NT$494.69 Million |
|
Garuda Indonesia Persero Tbk
JK:GIAA
|
Indonesia | Rp138.13 Trillion |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
USA | $583.17K |
|
Uno&Company.Ltd
KQ:114630
|
Korea | ₩12.61 Billion |
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
Indonesia | Rp990.41 Billion |
|
KGL Resources Ltd
AU:KGL
|
Australia | AU$1.47 Million |
|
Miwon Holdings Co. Ltd
KO:107590
|
Korea | ₩210.05 Billion |
|
Microbot Medical Inc
NASDAQ:MBOT
|
USA | $3.96 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down Immunoprecise Antibodies Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Immunoprecise Antibodies Ltd (IPA) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunoprecise Antibodies Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunoprecise Antibodies Ltd (1997–2025)
The table below shows the annual total liabilities of Immunoprecise Antibodies Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $20.82 Million | -20.15% |
| 2024-04-30 | $26.07 Million | +30.27% |
| 2023-04-30 | $20.01 Million | +9.89% |
| 2022-04-30 | $18.21 Million | +81.45% |
| 2021-04-30 | $10.04 Million | -17.59% |
| 2020-04-30 | $12.18 Million | +18.49% |
| 2019-04-30 | $10.28 Million | -13.44% |
| 2018-04-30 | $11.87 Million | +1318.60% |
| 2017-04-30 | $836.91K | +77.26% |
| 2016-04-30 | $472.15K | +85.42% |
| 2015-04-30 | $254.64K | -16.10% |
| 2014-04-30 | $303.50K | +14.26% |
| 2013-04-30 | $265.63K | +24.65% |
| 2012-04-30 | $213.10K | +93.36% |
| 2011-04-30 | $110.21K | +12.60% |
| 2010-04-30 | $97.87K | -35.12% |
| 2009-04-30 | $150.84K | +302.67% |
| 2008-04-30 | $37.46K | -90.94% |
| 2007-04-30 | $413.69K | +198.43% |
| 2006-04-30 | $138.62K | +193.83% |
| 2005-04-30 | $47.18K | -5.49% |
| 2004-04-30 | $49.92K | +69.03% |
| 2003-04-30 | $29.53K | -84.27% |
| 2002-04-30 | $187.72K | -79.07% |
| 2001-04-30 | $896.75K | +8770.78% |
| 2000-04-30 | $10.11K | -71.75% |
| 1999-04-30 | $35.78K | -46.90% |
| 1998-04-30 | $67.39K | -73.05% |
| 1997-04-30 | $250.04K | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more